top of page
Granules strengthens ADHD portfolio with FDA approval for Lisdexamfetamine Dimesylate Capsules
Granules India received the final approval from the US FDA for its ANDA for Lisdexamfetamine Dimesylate Capsules in strengths of 10-70 mg
Jan 302 min read
Granules India Limited honoured with Golden Peacock Award for Sustainability, setting new standards in environmental responsibility
Golden Peacock Award for Sustainability was presented to Granules India at the Institute of Directors’ Annual Global Convention held in UK
Nov 15, 20242 min read
Granules India’s Unit V facility secures US FDA EIR with 'No Action Indicated' status
Granules India's Unit V facility located at JNPC, Anakapalli District, Parawada Mandal, Andhra Pradesh, was inspected by US FDA in April
Nov 8, 20242 min read
bottom of page